In the morning of December 29, 2021, Deputy District Mayor Wang Nai of Huangpu District and his delegation visited the Shanghai branch of Sumitomo Pharma (Suzhou) Co., Ltd. (hereinafter referred to as ""Sumitomo Pharma (Suzhou) Co., Ltd.) in Huangpu Distr
On December 24, 2021, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (hereinafter referred to as Sumitomo Pharmaceuticals) and Shanghai Pharmaceutical Co., Ltd. (hereinafter referred to as SHAPHAR) jointly held the "Annual ALM-CSO Project Meeting" to celebra
Organized by the Shanghai Medical and Health Development Foundation(SHMHDF), implemented by Shanghai Institute of Hypertension, supported by the Sumitomo Dainippon Pharma Suzhou, and co-organized by the Shanghai Association of Enterprise Health Care and M
On November 23, 2021, Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), approved the New Drug Application (NDA) of the oral ta...
Development and commercialization plans include prescription digital therapeutics to treat social anxiety, generalized anxiety disorder, and major depressive disorder - with potential to impact millions worldwide.
On September 22, 2021, a cooperation agreement was concluded between Sumitomo Pharma (Suzhou) Co., Ltd. Sumitomo Pharma (Suzhou) Co., Ltd. and Profex (Shanghai) Co., Ltd. (Profex). According to the agreement, Sumitomo Pharma (Suzhou) Co., Ltd. and Profex
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
